Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan

Phase 4

• Conditions: Malaria
• Interventions: Drug: artemether- lumefantrine; Drug: Dihydroartemisinin- piperaquine

• Registration Number: NCT01075945
• Lead Sponsor: University of Khartoum

Brief Summary

Dihydroartemisinin- Piperaquine is not inferior to artemether-lumefantrine

Detailed Description

Not available

Study Timeline

• Status Verified: 2010-02
• Study Start: 2010-02
• Study First Submitted: 2010-02-18
• Study First Submitted QC: 2010-02-24
• Last Update Submitted: 2010-02-24
• Study First Posted: 2010-02-25
• Last Update Posted: 2010-02-25
• Primary Completion: 2010-04
• Study Completion: 2010-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

• Uncomplicated malaria

Exclusion Criteria

• Severe cases
• Pregnancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
artemether- lumefantrine	artemether- lumefantrine	oral tablets
Dihydroartemisinin- piperaquine	Dihydroartemisinin- piperaquine	orally tablets
Dihydroartemisinin- piperaquine	artemether- lumefantrine	orally tablets

Primary Outcome Measures

Name	Time	Method
comparing the cure rate between the two drugs	3 months	PCR cure rate Parasite clearance time Fever clearance time

Trial Locations

Locations (1)

Sinnar; 🇸🇩 Cinnar, Blue Nile, Sudan

Sinnar

🇸🇩Cinnar, Blue Nile, Sudan

Ishag Adam, Md, PhD

Contact

+249912168988

ishagadam@hotmail.com

Fatih M Malik, MD

Contact

+249911259199

ishagadamm@yahoo.com

Ishag I Adam, MD, PhD

Principal Investigator